TABLE 32Comparison of deterministic and probabilistic cost-effectiveness results for TRA + ANA versus ANA (base case with a 20-year time horizon)

Sensitivity analysisIncremental cost (£)Incremental QALYsICER (£)
Deterministic37,8990.66969,514
Probabilistic33,4890.51365,284

From: 4, Assessment of cost-effectiveness

Cover of Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis
Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis.
Health Technology Assessment, No. 15.42.
Fleeman N, Bagust A, Boland A, et al.
Southampton (UK): NIHR Journals Library; 2011 Dec.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.